CO4940483A1 - 5-(2-etil-2-h-tetrazol-5-il)-1-metil-1,2,3,6-tetrahidropiri- dina - Google Patents
5-(2-etil-2-h-tetrazol-5-il)-1-metil-1,2,3,6-tetrahidropiri- dinaInfo
- Publication number
- CO4940483A1 CO4940483A1 CO98036576A CO98036576A CO4940483A1 CO 4940483 A1 CO4940483 A1 CO 4940483A1 CO 98036576 A CO98036576 A CO 98036576A CO 98036576 A CO98036576 A CO 98036576A CO 4940483 A1 CO4940483 A1 CO 4940483A1
- Authority
- CO
- Colombia
- Prior art keywords
- maleic acid
- acid addition
- addition salt
- disorder
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Una sal de adición de ácido maleico de 2-etil-5-(1-metil-1,2,5,6-tetrahidro-3-piridil)-2H-tetrazol. La sal de adición de ácido maleico, de acuerdo con la reivindicación 1, la cual es la sal de adición de ácido mono-maleico. Una composición farmacéutica que comprende una sal de adición de ácido maleico, de acuerdo con las Reivindicaciones 1 a 2 junto con por lo menos un portador o diluyente farmacéuticamente aceptable.Un método para el tratamiento de un trastorno o enfermedad causada por mal funcionamiento de la acetilcolina (AcCh) o sistema muscarínico, que comprende la administración de una cantidad terapéuticamente efectiva de una sal de adición de ácido maleico, según las Reivindicaciones 1 a 2, a un sujeto que padece dicho trastorno.El método, de acuerdo con la Reivindicación 3, que se caracteriza porque trata el mal de Alzheimer, lesiones traumáticas de cerebro o trastornos psicóticos. El uso de sal de adición de ácido maleico, de acuerdo con Reivindicaciones 1 a 2, para la preparación de una composición farmacéutica para el tratamiento de un trastorno o enfermedad causado por mal funcionamiento de la acetilcolina (AcCh) o sistema muscarínico.El uso, de acuerdo con la Reivindicación 5, que se caracteriza porque la enfermedad o trastorno es mal de Alzheimer, lesiones traumáticas cerebrales o desórdenes psicóticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK78197 | 1997-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4940483A1 true CO4940483A1 (es) | 2000-07-24 |
Family
ID=8097489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98036576A CO4940483A1 (es) | 1997-07-01 | 1998-06-26 | 5-(2-etil-2-h-tetrazol-5-il)-1-metil-1,2,3,6-tetrahidropiri- dina |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0994869A1 (es) |
| JP (1) | JP2002507215A (es) |
| KR (1) | KR20010014297A (es) |
| CN (1) | CN1261361A (es) |
| AR (1) | AR013096A1 (es) |
| AU (1) | AU735751B2 (es) |
| BG (1) | BG103933A (es) |
| BR (1) | BR9810331A (es) |
| CA (1) | CA2293324A1 (es) |
| CO (1) | CO4940483A1 (es) |
| EA (1) | EA200000081A1 (es) |
| HU (1) | HUP0002876A2 (es) |
| IL (1) | IL133093A0 (es) |
| IS (1) | IS5278A (es) |
| JO (1) | JO2031B1 (es) |
| MA (1) | MA25138A1 (es) |
| NO (1) | NO996580D0 (es) |
| PE (1) | PE116099A1 (es) |
| PL (1) | PL337184A1 (es) |
| SK (1) | SK187399A3 (es) |
| TN (1) | TNSN98120A1 (es) |
| TR (1) | TR199903283T2 (es) |
| UY (2) | UY25069A1 (es) |
| WO (1) | WO1999001448A1 (es) |
| ZA (1) | ZA985498B (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8714789D0 (en) * | 1987-06-24 | 1987-07-29 | Lundbeck & Co As H | Heterocyclic compounds |
| PL326490A1 (en) * | 1995-11-06 | 1998-09-28 | Lundbeck & Co As H | Treatment of traumatic brain injuries |
-
1998
- 1998-06-18 AR ARP980102925A patent/AR013096A1/es not_active Application Discontinuation
- 1998-06-24 ZA ZA985498A patent/ZA985498B/xx unknown
- 1998-06-25 PE PE1998000563A patent/PE116099A1/es not_active Application Discontinuation
- 1998-06-25 JO JO19982031A patent/JO2031B1/en active
- 1998-06-26 CO CO98036576A patent/CO4940483A1/es unknown
- 1998-06-29 UY UY25069A patent/UY25069A1/es not_active Application Discontinuation
- 1998-06-30 TN TNTNSN98120A patent/TNSN98120A1/fr unknown
- 1998-07-01 JP JP50616699A patent/JP2002507215A/ja active Pending
- 1998-07-01 BR BR9810331-8A patent/BR9810331A/pt not_active Application Discontinuation
- 1998-07-01 TR TR1999/03283T patent/TR199903283T2/xx unknown
- 1998-07-01 IL IL13309398A patent/IL133093A0/xx unknown
- 1998-07-01 MA MA25155A patent/MA25138A1/fr unknown
- 1998-07-01 AU AU81020/98A patent/AU735751B2/en not_active Ceased
- 1998-07-01 CN CN98806497A patent/CN1261361A/zh active Pending
- 1998-07-01 PL PL98337184A patent/PL337184A1/xx unknown
- 1998-07-01 WO PCT/DK1998/000294 patent/WO1999001448A1/en not_active Application Discontinuation
- 1998-07-01 EP EP98930655A patent/EP0994869A1/en not_active Withdrawn
- 1998-07-01 KR KR1019997012429A patent/KR20010014297A/ko not_active Application Discontinuation
- 1998-07-01 EA EA200000081A patent/EA200000081A1/ru unknown
- 1998-07-01 CA CA002293324A patent/CA2293324A1/en not_active Abandoned
- 1998-07-01 HU HU0002876A patent/HUP0002876A2/hu unknown
- 1998-07-01 SK SK1873-99A patent/SK187399A3/sk unknown
- 1998-09-10 UY UY25177A patent/UY25177A1/es not_active Application Discontinuation
-
1999
- 1999-11-30 IS IS5278A patent/IS5278A/is unknown
- 1999-11-30 BG BG103933A patent/BG103933A/xx unknown
- 1999-12-30 NO NO996580A patent/NO996580D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999001448A1 (en) | 1999-01-14 |
| PE116099A1 (es) | 1999-11-23 |
| EA200000081A1 (ru) | 2000-08-28 |
| SK187399A3 (en) | 2000-06-12 |
| TNSN98120A1 (fr) | 2005-03-15 |
| KR20010014297A (ko) | 2001-02-26 |
| UY25069A1 (es) | 1998-12-21 |
| JO2031B1 (en) | 1999-05-15 |
| NO996580L (no) | 1999-12-30 |
| TR199903283T2 (xx) | 2000-06-21 |
| IL133093A0 (en) | 2001-03-19 |
| AU735751B2 (en) | 2001-07-12 |
| UY25177A1 (es) | 2000-12-29 |
| CA2293324A1 (en) | 1999-01-14 |
| PL337184A1 (en) | 2000-08-14 |
| AR013096A1 (es) | 2000-12-13 |
| IS5278A (is) | 1999-11-30 |
| AU8102098A (en) | 1999-01-25 |
| MA25138A1 (fr) | 2001-04-02 |
| NO996580D0 (no) | 1999-12-30 |
| BR9810331A (pt) | 2000-09-05 |
| EP0994869A1 (en) | 2000-04-26 |
| CN1261361A (zh) | 2000-07-26 |
| BG103933A (en) | 2000-07-31 |
| JP2002507215A (ja) | 2002-03-05 |
| HUP0002876A2 (hu) | 2001-06-28 |
| ZA985498B (en) | 1999-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| DE69017302T3 (de) | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. | |
| CO5261590A1 (es) | Un derivado de pirrolidinacetamida solo o en combinacion para el tratamineto de transtornos del sistema nervioso central (cns) | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| EE200200578A (et) | Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| WO2000056303A3 (en) | Treatment of immune diseases | |
| CY1107653T1 (el) | Ενωσεις ειδικες για υποδοχεις α1, α2α και α3 αδενοσινης και χρησεις αυτων | |
| WO2001054681A8 (en) | Composition for treatment of stress | |
| FI911700A (fi) | Anvaendning av n-alkylerade 1,4 -dihydropyridinkarboxylsyraestrar som laekemedel, nya foereningar och foerfarande foer deras framstaellning. | |
| ES2094702B1 (es) | Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion. | |
| NO20002696L (no) | Nye forbindelser med cGMP-PDE-inhibitoreffekt | |
| BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
| ES2121103T3 (es) | Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas. | |
| BR9912581A (pt) | Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica | |
| CO4940483A1 (es) | 5-(2-etil-2-h-tetrazol-5-il)-1-metil-1,2,3,6-tetrahidropiri- dina | |
| BRPI0414139A (pt) | métodos e composições para tratar infecções por herpes | |
| WO2002017857A3 (en) | Methods and compositions for inhibiting angiogenesis | |
| DE69926794D1 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
| BR0011845A (pt) | Complexo farmacêutico | |
| BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
| MX9303074A (es) | Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer. | |
| BR9912008A (pt) | Método de tratamento | |
| ES2052475T1 (es) | Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14. | |
| Hoover | CI-979/RU 35926: A novel muscarinic agonist for the treatment of Alzheimer’s disease |